The company's cardiovascular business faces new rivals in pulsed field ablation and heart devices. A restructuring plan aims ...
The restructuring is expected to cost Boston Scientific (NYSE: BSX) somewhere between $700 million to $800 million, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results